Dmitry Balyasny’s Novo Nordisk NVO Stock Holding History

Dmitry Balyasny’s Portfolio NVO Stock Details NVO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$10.4M	Sell	216,100 -377,400	-64%	-$16.2M	0.01%	1046
2026 Q1	$21.8M	Buy	593,500 +516,500	+671%	+$24.5M	0.03%	654
2025 Q4	$3.92M	Sell	77,000 -7,000	-8%	-$358K	0.01%	1519
2025 Q3	$4.66M	Sell	84,000 -94,800	-53%	-$5.55M	0.01%	1396
2025 Q2	$12.3M	Buy	178,800 +153,900	+618%	+$10.5M	0.02%	874
2025 Q1	$1.73M	Buy	24,900 +22,100	+789%	+$1.83M	﹤0.01%	1767
2024 Q4	$241K	Buy	+2,800	New	+$303K	﹤0.01%	2472
2024 Q1	–	Sell	-222,000	Closed	-$23M	–	2960
2023 Q4	$23M	Sell	222,000 -363,000	-62%	-$35.9M	0.04%	550
2023 Q3	$377M	Buy	+585,000	New	+$51.5M	0.77%	11

Other funds holding NVO

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $79.8B AUM 16.05% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Folketrygdfondet Oslo Norway, Norway $4.64B AUM 35.47% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

Dmitry Balyasny's NVO Position: Q2 2026 in Review

Dmitry Balyasny increased its Novo Nordisk (NVO) stake by 190% in Q2 2026, buying an estimated $31.2M and bringing the position to 1,109,982 shares worth $53.2M. The position accounts for 0.07% of the portfolio, ranked #341.

Dmitry Balyasny first reported a position in NVO in Q1 2018 and has held it in 22 quarters since. The position peaked at $106M in Q2 2025. 1,350 funds tracked by Wall St. Rank hold NVO as of Q2 2026.

Dmitry Balyasny held 1,109,982 shares of Novo Nordisk worth $53.2M as of Q2 2026.
Dmitry Balyasny bought 726,836 Novo Nordisk shares in Q2 2026, an estimated $31.2M.
Novo Nordisk made up 0.07% of Dmitry Balyasny's portfolio in Q2 2026, its #341 holding.
Dmitry Balyasny first reported a position in Novo Nordisk in Q1 2018 and has held it in 22 quarters since.
Dmitry Balyasny's Novo Nordisk position peaked at $106M in Q2 2025.
1,350 funds tracked by Wall St. Rank held Novo Nordisk as of Q2 2026.

Based on Balyasny Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.